- Home
- ENLV vs ALUR Comparison
ENLV vs ALUR Comparison
Compare ENLV & ALUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENLV
- ALUR
- Stock Information
- Founded
- ENLV 2005
- ALUR 2009
- Country
- ENLV Israel
- ALUR United States
- Employees
- ENLV N/A
- ALUR N/A
- Industry
- ENLV Biotechnology: Pharmaceutical Preparations
- ALUR
- Sector
- ENLV Health Care
- ALUR
- Exchange
- ENLV Nasdaq
- ALUR Nasdaq
- Market Cap
- ENLV 24.4M
- ALUR 24.7M
- IPO Year
- ENLV 1995
- ALUR N/A
- Fundamental
- Price
- ENLV $1.00
- ALUR $3.55
- Analyst Decision
- ENLV Strong Buy
- ALUR Strong Buy
- Analyst Count
- ENLV 2
- ALUR 3
- Target Price
- ENLV $9.50
- ALUR $50.00
- AVG Volume (30 Days)
- ENLV 50.8K
- ALUR 4.1M
- Earning Date
- ENLV 03-28-2025
- ALUR 03-20-2025
- Dividend Yield
- ENLV N/A
- ALUR N/A
- EPS Growth
- ENLV N/A
- ALUR N/A
- EPS
- ENLV N/A
- ALUR N/A
- Revenue
- ENLV N/A
- ALUR $34,754,000.00
- Revenue This Year
- ENLV N/A
- ALUR N/A
- Revenue Next Year
- ENLV N/A
- ALUR N/A
- P/E Ratio
- ENLV N/A
- ALUR N/A
- Revenue Growth
- ENLV N/A
- ALUR N/A
- 52 Week Low
- ENLV $0.81
- ALUR $2.37
- 52 Week High
- ENLV $4.59
- ALUR $98.75
- Technical
- Relative Strength Index (RSI)
- ENLV 32.92
- ALUR 36.72
- Support Level
- ENLV $1.00
- ALUR $3.32
- Resistance Level
- ENLV $1.09
- ALUR $5.78
- Average True Range (ATR)
- ENLV 0.08
- ALUR 0.71
- MACD
- ENLV -0.00
- ALUR -0.13
- Stochastic Oscillator
- ENLV 12.50
- ALUR 6.05
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
About ALUR Allurion Technologies Inc.
Allurion Technologies Inc is a medical device company that focuses on creating a best-in-class weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.